Strategic niche Target health tech and diagnostics buyers seeking rapid, at-home testing capabilities by highlighting GeneFluidics' platform that enables complex tests to be performed by non-specialists, aligning with consumer-focused or point-of-care initiatives.

Regulatory milestone Leverage the CE marking for UtiMax to pursue opportunities in EU markets, emphasizing compliance readiness and accelerated deployment to healthcare providers and distributors looking for validated diagnostic solutions.

Small team agility Position as a nimble partner for niche diagnostics projects, offering fast decision cycles and customizable collaboration models to larger biotechs or contract manufacturers seeking specialized microfluidic test platforms.

Clinical traction Highlight infectious disease focus and the potential for expanded assays, presenting cross-sell options to labs and public health organizations that require scalable, user-friendly diagnostics with minimal lab infrastructure.

Growth potential Capitalize on the low revenue base by targeting grant-funded programs, pilot deployments, and regional distributors in Europe and beyond, aiming to convert early adopters into long-term customers as the platform matures.